APASL2017 in Shanghai
Late Breaker Submission will be closed on DECEMBER 20, 2016
Early Bird Registration Deadline: DECEMBER 30, 2016
Pre-registration Deadline: JANUARY 20, 2017
An application has been made to the EACCME for CME accreditation of APASL 2017.
Delegates who attend the conference will receive EACCME certificates.
We are delighted and honored to introduce you to the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), which will take place at Shanghai International Convention Center, on 15-19 February 2017 in Shanghai, China. We will bring together a distinguished faculty of renowned specialists from Asia Pacific and around the world to this conference.
APASL annual meeting has grown as the leading conference focusing on remarkable progress in liver disease, aimed to provide the latest scientific and evidence-based research result that will be applicable to the everyday clinical practice. It provides an excellent opportunity to share and exchange experiences especially from the view of Asian Pacific countries. These elements are essential to pave a way for better development of Hepatology.
We planned to have a three-day core program to provide an overview of varies liver diseases with the State-of- the Art Lectures on hot-off-the-press issues. Besides, Postgraduate Courses and Morning Sessions will be de- signed for the in-depth discussion on particular topics.
Free paper and poster presentation is always the soul of the conference to share research findings and there will be several awards available for application aimed to support young scientists to attend the conference and encourage scientific research.
We thus enthusiastically invite you to submit abstract and join us in this conference as well as our blooming city – Shanghai.
We look forward to welcoming you in Shanghai!
Prof. Jinlin Hou
President of APASL ANNUAL MEETING 2017
APASL ANNUAL MEETING 2017 in Shanghai
APASL STC 2017 in Nagasaki
Abstract Submission Deadline: Extended to January 31, 2017
Early Bird Registration Deadline: Extended to February 14, 2017
Pre-Registration Close: March 10, 2017
Abstract Submission and Pre-Registration is now available!
Why I chose the prevention of HCC as a theme at NAGASAKI-STC conference?
With the recent development of DAAs therapy for hepatitis C, it is now possible to achieve a high rate of HCV elimination, i.e. SVR, in patients with hepatitis C, as well as nucleic acid analog treatment for the hepatitis B enabled high rate and reliable suppression of HBV proliferation in hepatitis B patients.
However, even if SVR is achieved after treatment with DAAs in patients with hepatitis C, there are some cases where HCC still occurs afterwards, and the existence of HCC with high malignancy of cells, which rapidly increases after SVR, has been a major problem in my recent experience. There are also some cases in which HCC still newly emerges during nucleic acid analog therapy in patients with chronic hepatitis B.
On the other hand, the incidence of HCC cases of Non-B Non-C has increased by 8 times compared to 20 years ago, according to our cohort study of the Kyushu region. In hepatocytes in which the hepatitis virus is absent, abnormalities in lipid metabolism may be involved in HCC development. I think that there may be intersections between the mechanism of HCC development in the patients with SVR after treatment of hepatitis C, the mechanism of HCC development during nucleic acid analogue treatment and the mechanism of HCC development in the patients with Non-B Non-C HCC.
Currently when the hepatitis virus has been eliminated and control has become possible, the most important thing is to further strengthen the suppression of HCC occurrence, and by justification of HCC risk and application in practical clinics, prediction of carcinogenesis. Japanese patients with chronic hepatitis C and B belong to a group with the highest carcinogenic risk in the world. I hope that presenting the results of basic research and clinical research on the prevention of HCC development in NAGASAKI-STC conference and considering future liver disease research will be milestones in this field.
Hiroshi Yatsuhashi M.D.
President, APASL Single Topic Conference in Nagasaki
Director General, Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center
Professor, Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences
APASL STC on Prevention of HCC development in Japan
APASL STC 2016 in Beijing
APASL STC 2016 on HBV in Beijing has been successfully held!!
APASL STC 2016 - 6th HBV Conference will be held on 16 - 18 December 2016 in Beijing, China. The theme of this conference is “Enhancing Knowledge for Better Patient Care”. The most up-to-date findings from the translational medicine to the clinical management of viral hepatitis B infection, including prevention and control, novel targets and drug discovery, biomarkers and diagnosis, and the treatment guidelines will be discussed during the conference. The experts will bring their didactic lectures to join together and make this conference an unforgettable academic event. Join us now and meet together in Beijing, China!!
Dear, Colleagues and Distinguished Guests,
On behalf of the Organizing Committee and Scientific Committee, it is our great pleasure to welcome you to join the APASL STC 2016 – 6th HBV Conference, which will be held on December 16-18, 2016 in Beijing, China.
As an influential and responsible academic association, APASL always promotes research and education in hepatology and focuses on combating liver diseases. The APASL Single Topic Conference (STC) is dedicated to the advancement of liver diseases treatment in Asian-Pacific countries and provide an excellent communication platform for global and regional hepatologists. The theme of this conference is “Enhancing Knowledge for Better Patient Care”. Currently, chronic HBV infection remains a serious public health problem due to its worldwide distribution and potential severe outcomes, particularly in the Asian-Pacific region. In the last two decades, with the effort of researchers and clinicians, great progresses in this field have been made. The most up-to-date findings from the translational medicine to the clinical management of viral hepatitis B infection, including prevention and control, novel targets and drug discovery, biomarkers and diagnosis, and the treatment guidelines will be discussed. The experts will bring their didactic lectures to join together and make this conference an unforgettable academic event.
For APASL, China is a major center for basic and clinical research of liver diseases. We are therefore delighted to host 2016 APASL STC in Beijing., the capital of China and an international hub that connecting China and the world. We believe that extensive discussions and wonderful experience will be shared between Chinese doctors and international colleagues.
Prof. Lai Wei
Congress Chairman APASL STC-6th HBV Conference
APASL STC on HBV in China
APASL STC 2017 in Cairo
We are delighted and honored to introduce you to the Single topic Conference on HCV (Real Life Experience) of the Asian Pacific Association for the Study of the Liver (APASL) which will be held at Intercontinental City Stars hotel Convention Center, on 6-8 September 2017 in Cairo, Egypt. We will bring together a distinguished faculty of renowned specialists from AsiaPacific and around the world to this conference.
After the two successful liver fibrosis STC meetings in Cairo on 2008 and 2014, the coming congress have been selected to focus on HCV and its remarkable fast progress in the new treatment modalities. Egyptians have the highest world prevalence of HCV of 14.7%. Luckily, we have the first world national program treating all our patients. It will be a good opportunity to discuss with the world experts in this field the results of their researches, and the real life results of different national protocols that are currently ongoing specially in the AsiaPacific region.
By reaching the date of the congress on September 2017, there will be more than one million Egyptian patients that have been cured from the virus using the currently available DAAs. The congress will provide an excellent opportunity to share and exchange experiences especially from the view of Asian Pacific countries regarding the latest scientific and evidence-based research results and recommendations to follow-up the cured patients, to treat their damaged liver cells, to dissolve their fibrous bands, to detect and treat early any rising liver cancers. These elements are essential to pave a way for better treatment of HCV patients not only in the AsiaPacific region but among the world.
We planned to have 1 day of post-graduate educational program as well as 2 days for the core of the meeting. The core program is to provide an overview of different aspects of HCV with the State-of-the Art Lectures on hot-off-the-press issues. Free papers and poster presentations is always the soul of the conference to share research findings and there will be several awards available for application aimed to support young scientists to attend the conference and encourage scientific research. We thus enthusiastically invite all of you to submit abstract and join us in this conference.
In addition to the scientific program, an interesting social program for the doctors and their companions have been well prepared. Visiting the historical parts of old Cairo, the Coptics and the Islamic heritage as well as the pyramids, the sphinx and the old Egyptian museum will be memorial time. Luckily enough by September 2017, the outstanding new-Egyptian cultural museum will have its doors opened to show the largest collections of the era of Pharos. For those who have been prepared to have available time, it will be an outstanding chance having one of two options. Either to visit the two beauty cities in the upper Egypt, Luxur and Aswan to see the Temples, or to travel to one of the resorts or diving places in the north cost or the red sea (Hurgada and Sharm ElSheikh) that have been recognised as one of the highly ranked places for leisure.
We are waiting meeting you in Cairo, Egypt on September 6-8, 2017
Best of our Greetings
Prof. GAMAL SHIHA
President of the Congress
Prof. ALAAELDIN IBRAHIM
Vice-President of the Congress
APASL STC on HCV Treatment - The Real Life Results in Egypt
Date: September 6-8, 2017
City: Cairo, Egypt
President: Dr. Gamal Shiha
Website: To be announced
Future APASL Conferences
APASL 2018 Annual Meeting in India
Date: March 15-18, 2018
City: New Delhi, India
President: Dr. Barjesh C. Sharma
APASL 2019 Annual Meeting in Philippines
Date: February-March, 2019 (to be announced)
City: Manila, Philippines
President: Dr. Diana A. Payawal
APASL STC on HCV and Coinfection in Mongolia
Date: June 16-18, 2017
City: Ulaanbaatar, Mongolia
President: Dr. Oidov Baatarkhuu
APASL STC on HCC in Japan
Date: May 11-13, 2018
City: Yokohama, Japan
President: Dr. Shuichiro Shiina
APASL STC HBV in Asia-Pacific in Taiwan
Date: June 22-24, 2018
City: Taipei, Taiwan
President: Dr. Rong-Nan Chien
APASL STC on HCV in Malaysia
Date: 2018 (to be announced)
City: Kuala Lumpur, Malaysia
President: Dr. Rosmawati Mohamed
APASL Fellowship 2017
The objective of the fellowship is to foster career development by encouraging the beneficial experience of working in a different clinical or research environment in another country in the Asia-Pacific region. These fellowships provide for advanced training in health and medical research in any country in the Asia-Pacific region and enable fellows to work in a clinical environment or on a research project with nominated advisers. We appreciate your generous contributions and support for these APASL fellowships and look forward to a number of high-quality applications for a 2017 fellowship.
An application form can be downloaded by clicking here: http://www.apasl.info/applicationform-fellowship.docx Please fill in and send to the APASL secretariat (firstname.lastname@example.org). We are looking forward to receiving your application. There are no restrictions based on nationality. The sponsoring institution with the academic environment to provide adequate support for the proposed project might be suggested by APASL. Application will be reviewed by APASL Committee members. The decisions of the Committee are final and not subject to appeal.